Kynos Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Kynos Therapeutics was an Edinburgh clinical-stage biotech founded in 2020 as a University of Edinburgh spin-out by professors Damian Mole and Scott Webster, with founding investor Epidarex Capital alongside IP Group and Scottish Enterprise. It developed first-in-class KMO (kynurenine 3-monooxygenase) inhibitors for acute and chronic inflammatory diseases; its lead molecule KNS366 completed a Phase I trial. The company was acquired by Germany's Dr. Falk Pharma in October 2024, which folded KNS366 into its pipeline for acute pancreatitis.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Kynos Therapeutics is founded in Edinburgh as a University of Edinburgh spin-out to develop KMO inhibitors for inflammatory diseases, backed by Epidarex Capital.
- Acquisition
Dr. Falk Pharma acquires Kynos Therapeutics in October 2024, adding lead molecule KNS366 to its R&D pipeline for acute pancreatitis.
- Wind-down announced
The UK entity enters a solvent members' voluntary liquidation in September 2025 after the acquisition integration.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.